May 15, 2013—Drug manufacturer Mylan has mailed refunds to 340B providers for overcharges on all products sold by its Mylan Specialty subsidiary (formerly known as Dey Pharma) from late 1994 through late 2006.
Last November, the Office of Pharmacy Affairs (OPA) posted a message from Mylan on its home page explaining that the company needed to give refunds to 340B entities due to a recalculation of average manufacturer prices and best prices that Dey Pharma reported to the Centers for Medicare and Medicaid Services (CMS) under the Medicaid rebate program.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)